Calls of the Day: Abbvie, Vertex, Veeva, and Vistra Stock Analysis

Biotech Stock Analysis: Abbvie and Vertex

• 💡 Jim is bullish on Abbvie and Vertex, viewing them differently from typical biotech companies.
• 🎯 These companies have approved drugs generating revenue, in addition to pipeline drugs, unlike early-stage biotechs.
• 💰 Abbvie is highlighted for its mid-teens multiple and approximately 3% dividend yield.
• 🚀 Vertex is noted for its recently approved pain medication and attractive valuation.

Veeva Systems: Cloud Software for Life Sciences

• 📌 Joe discusses Veeva, a cloud-based software company serving the life sciences sector.
• 📈 Despite a high valuation (double nickels), Veeva has shown consistent revenue growth (16% last quarter, 14-15% in prior years).
• 📊 The company has 50% revenue exposure in the US and 50% internationally, operating as a midcap around $45 billion.
• 📉 Veeva shares are trading approximately 15% below their all-time high from August 2021.

Utility Stock Discussion: Vistra and Others

• ⚠️ Joe mentions owning three utility names: Constellation, Vistra, and Atmos Energy.
• 📉 Constellation and Vistra are currently experiencing a pullback.
• 📊 Atmos Energy is identified as looking the best among the three utility names discussed.